| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5546964 | Annales Pharmaceutiques Françaises | 2017 | 10 Pages |
Abstract
Given their currently restricted use, the hospital budget impact of biological meshes remains limited although the incremental cost per patient is substantial. Analytic costs data can be useful within the scope of decision-making related to DM not refunded by the French health system.
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Drug Discovery
Authors
A. Sainfort, I. Denis-Hallouard, G. Aulagner, O. Nuiry, X. Armoiry,